



SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data driven medicine as the standard of care and for life sciences research.

It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 750 hospital, laboratory and biopharma institutions globally. It is believed to be one of the most widely used decentralized analytics platforms globally for clinical genomics.

SOPHiA GENETICS was founded in 2011 as a startup at École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne, Switzerland.

Founders	Jurgi Camblong (Chief Executive Officer) Pierre Hutter Lars Steinmetz
Key People	Bram Goorden (Chief Operating Officer) Lara Hashimoto (Chief Business Officer) Philippe Menu (Chief Medical Officer) Ross Munken (Chief Financial Officer) Manuela Valente (Chief People Officer) Zhenyu Xu (Chief Scientific Officer) Daan Van Well (General Counsel) Melissa Finocchio (Regulatory & Quality Affairs)
Offices	Boston, Massachusetts Lausanne, Switzerland Bidart, France
Employees	462 worldwide as of June 30, 2021 30% of employees hold a PhD
Finance	Pre-IPO Funding: \$250.2M Ticker Symbol: SOPH on Nasdaq
About SOPHiA DDM™ Platform	The SOPHiA DDM™ Platform, a cloud-based Software-as-a-Service platform that provides a safe, secure, and instantly accessible environment to generate insights across complex genomic and phenotypic datasets. Customers test their own samples and retain

ownership of their data.

The SOPHiA DDM™ platform provides analysis and insights across multiple disease areas, from oncology to inherited disorders. The platform is designed to continually improve as it analyzes more data over time, leveraging the power of SOPHiA AI and sharing the benefits of this growing collective intelligence with our customers.

The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 750 hospital, laboratory and biopharma institutions globally.

About SOPHiA AI

A key component of the SOPHiA DDM™ Platform, SOPHiA AI standardizes, computes and analyzes digital health data, generating insights from complex multimodal data sets that have the potential to improve diagnosis, therapy selection and drug development.

Awards and Recognition

Fast Company

- Ranked #5 Most Innovative Company in Biotech, 2018

MIT Tech Review

- Ranked #30 in 50 Smartest Companies, 2017

*Convergence in
Oncology Summit*

- Won Salus Partner Excellence in HealthTech Award 2018

*Healthcare
Medtech Asia
Awards*

- Won Hospital Partnership of the Year, Australia 2021
- Won Oncology Product Innovation of the Year, Australia 2021

*Tech Tour Growth
50*

- Won Growth Award 2019

Media Inquiries

sophiagenetics@consortpartners.com